Idiopathic Infertility Clinical Trial
Official title:
Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI
Placebo-controlled study. Application of nasal oxytocin (8 IU) during intrauterine insemination in 86 patients.
Between 2004 and 2007, 86 patients with primary or secondary infertility were enrolled in
this prospective, randomized, double-blinded study in our tertiary-care infertility center.
A total of 132 homologous intrauterine insemination (IUI) cycles (mean: 1.5 cycles) was
performed. All patients gave informed consent. The study was approved by the Human Ethics
Committee of the Medical Faculty of the Ludwig-Maximilians-University (LMU) Munich and the
German Federal Institute for Drugs and Medical Products (BfArM) (Bundesinstitut für
Arzneimittel und Medizinprodukte) consented to the study.
Inclusion criteria for couples were idiopathic infertility, polycystic ovary syndrome (PCOS)
and / or male subfertility (table 1). Maximum female age was 42 years. Infertility workup
included a standard gynecological examination with a transvaginal sonography using a 7.5 MHz
probe. Patients displaying signs or symptoms of anomalies such as uterine fusion defects,
submucosal fibroids, active endometriosis or acute inflammation were excluded from the
study. Further prerequisites were endocrine serum parameters (FSH, LH, estradiol,
testosterone, SHBG, DHEA-S, Prolaktin, TSH) from cycle day 2-5 within the normogonadotropic
range with no evidence of hyperandrogenemia, thyroid dysfunction or hyperprolactinemia. 15
patients were diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam
ESHRE/ASRM Consensus Workshop Group (26). In all patients fallopian tubes were documented to
be patent by sonographic contrast hysterosalpingography (Echovist® 200, Bayer Vital GmbH,
Leverkusen, Germany) or by chromo-laparoscopy. Infections with Hepatitis B and C and HIV
were excluded in all couples by negative serological tests. In all patients protective
titers against rubella virus were confirmed.
IUI was performed in natural (n=31, 23%) or stimulated cycles (n=101, 77%). Stimulation was
done with daily s.c. 37 IU or 50 IU of recombinant FSH (Puregon, Organon GmbH,
Oberschleißheim, Germany) starting on day 3 to day 5 of the menstrual cycle. Cycles were
monitored by repeated transvaginal sonography and determination of serum estradiol and LH.
Ovulation induction (OI) was done by 5.000 IU hCG (Predalon, Organon GmbH, Oberschleißheim,
Germany) s.c. or 250 μg recombinant hCG (Ovitrelle, Serono GmbH, Unterschleißheim, Germany)
s.c. as soon as one of maximum three follicles reached a mean diameter of 20 mm or LH
exceeded 10 mIU/mL in combination with a follicle mean diameter of at least 16 mm. IUI was
done 24h-36h after OI. Data on uterine, ovarian and endocrine parameters at the time of
ovulation induction (OI) are summarized in table 2.
Homologous semen samples were gained by masturbation after an abstinence time of 3-5 days.
After liquification for 30 min analysis of semen parameters were carried out according to
the World Health Organization guidelines (27). Details on results are summarized in table 2.
Sperm morphology was analysed according to WHO guidelines in at least one semen analysis
preceding this study not more than 3 months. The sperm preparation was conducted utilizing
density gradient separation as described in the WHO manual (27). Sil Select (FertiPro N.V.,
Beernem, Belgium) was used instead of Percoll as recommended in the WHO manual (27). The
density gradient (90%/45%) achieved separation of sperm after centrifugation at 500 g for 20
minutes. The pellet was washed in 5.0 mL Universal IVF Medium (Medi Cult, Jyllinge,
Denmark), centrifuged for 5 minutes at 500 g and resuspended in a total volume of 0.3 mL.
After processing, semen was evaluated for sperm concentration and motility. Only couples
with a total progressive motile sperm count (TPMC) of at least 1 million in the processed
sperm suspension were included in the study. Data are summarized in table 2.
Oxytocin and placebo, filled in identical nasal spray applicators labelled with "A" or "B",
were delivered by the pharmacy department of LMU-Klinikum, Campus Grosshadern. Probes were
blinded to the clinical staff and the patients. The verum consisted of Synthocinon®-Spray
(Novartis Pharma GmbH, Nürnberg, Germany). According to the manufacturer one nasal spray
pump consists of 4 IU of oxytocin. In addition the verum contained chlorobutanol,
methyl-4-hydroxybenzoat and propyl-4-hydroxybenzoat for preservation. Placebo consisted of
isotonic NaCl solution with 0.01 % benzalkoniumchloride und 0.1% Na-EDTA for preservation.
The nasal sprays were kept at 4°C and replaced monthly. Patients were randomly assigned to
either group A or group B (double-blinded) by using a computer generated randomization list.
Codes for A and B were broken after the last study patient had completed the pregnancy test.
Data on patient variables in both groups are summarized in table 2. All patients were asked
to squeeze the spray into the air for control of the pump mechanism and then to apply two
snuffs (=8 IU oxytocin) of nasal spray labelled with A and B respectively into one nostril
directly after IUI.
Ten minutes after completion of the IUI patients were asked to fill out a form documenting
possible side effects. Each of the following complaints was asked to be quantified in a
scale from level 1 (=no side effect) to level 10 (=maximum side effect): lower abdominal
pain, nasal mucosal irritation, nausea, headache and vomiting.
The primary endpoint of the study was evidence of a chorionic sac in transvaginal sonography
21-23 days after IUI with a positive serum hCG test.
Statistical analysis was carried out using SPSS 16.0. Binary logistic regression was applied
for calculation of Odds ratio and likelihood ratio test. For all comparisons, p < 0.05 was
considered significant.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05156684 -
Effect of Pentoxifylline and Zinc Co-administration in Patients With Oligoasthenoteratozoospermia
|
N/A | |
| Withdrawn |
NCT03104998 -
Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility
|
Phase 4 |